Presentation
13 March 2024 High contrast targeted SWIR fluorescence tumor screening and resection with a commercially available dye
Author Affiliations +
Abstract
Here we have validated a commercially available dye, CJ215 from ProImaging for enhanced cancer delineation. The dye (which does not require antibody or peptide conjugation) was found to be effective for both NIR and SWIR fluorescence imaging methods in preclinical breast, fibrosarcoma and prostate tumor models. The dye was effective for screening and resection and achieved some of the best-in-class tumor to organ ratios, e.g., tumor to muscle of 88.1, to liver of 17.9, to lungs of 12.9 and to kidney of 5 highlighting its renal clearance method. We briefly summarize the proposed mechanism of uptake and highlight the potential for clinical translation.
Conference Presentation
© (2024) COPYRIGHT Society of Photo-Optical Instrumentation Engineers (SPIE). Downloading of the abstract is permitted for personal use only.
Ben Mc Larney, Elana Apfelbaum, Ali Sonay, Magdalena Skubal, Mijin Kim, Hsiao-Ting Tsu, Daniel Heller, and Jan Grimm "High contrast targeted SWIR fluorescence tumor screening and resection with a commercially available dye", Proc. SPIE PC12862, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications XV, PC128620I (13 March 2024); https://doi.org/10.1117/12.3000503
Advertisement
Advertisement
KEYWORDS
Tumors

Dyes

Resection

Short wave infrared radiation

Fluorescence

Fluorescence imaging

Liver

Back to Top